Carsten Krumbiegel
Carsten Krumbiegel has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Heike Pospisil
High Performance Computing in Life Sciences, Technical University of Applied Sciences Wildau, Wildau, Germany
2 shared publications - Ina Koch
Goethe University, Institute of Computer Science, Frankfurt am Main, Germany
2 shared publications - Julienne Siptroth
High Performance Computing in Life Sciences, Technical University of Applied Sciences Wildau, Wildau, Germany
2 shared publications - Jörg Ackermann
Department of Molecular Bioinformatics, Institute of Computer Science, Goethe University Frankfurt, Frankfurt am Main, Germany
2 shared publications - Olga Moskalenko
BIOMES NGS GmbH, Wildau, Germany
2 shared publications
Latest Publications
- Open Access
- 9 May 2023
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 3 (1) , 1-9
Investigation of metabolic pathways from gut microbiome analyses regarding type 2 diabetes mellitus using artificial neural networks
- 9 May 2023
- Published by Springer Nature in Discover Artificial Intelligence
- Vol. 3 (1) , 1-9
Open AccessInvestigation of metabolic pathways from gut microbiome analyses regarding type 2 diabetes mellitus using artificial neural networks
- Open Access
- 13 February 2023
- Published by Springer Nature in International Microbiology
- Vol. 26 (3) , 601-610
Variation of butyrate production in the gut microbiome in type 2 diabetes patients
Background: Diabetes mellitus type 2 is a common disease that poses a challenge to the healthcare system. The disease is very often diagnosed late. A better understanding of the relationship between the gut microbiome and type 2 diabetes can support early detection and form an approach for therapies. Microbiome analysis offers a potential opportunity to find markers for this disease. Next-generation sequencing methods can be used to identify the bacteria present in the stool sample and to generate a microbiome profile through an analysis pipeline. Statistical analysis, e.g., using Student’s t-test, allows the identification of significant differences. The investigations are not only focused on single bacteria, but on the determination of a comprehensive profile. Also, the consideration of the functional microbiome is included in the analyses. The dataset is not from a clinical survey, but very extensive. Results: By examining 946 microbiome profiles of diabetes mellitus type 2 sufferers (272) and healthy control persons (674), a large number of significant genera (25) are revealed. It is possible to identify a large profile for type 2 diabetes disease. Furthermore, it is shown that the diversity of bacteria per taxonomic level in the group of persons with diabetes mellitus type 2 is significantly reduced compared to a healthy control group. In addition, six pathways are determined to be significant for type 2 diabetes describing the fermentation to butyrate. These parameters tend to have high potential for disease detection. Conclusions: With this investigation of the gut microbiome of persons with diabetes type 2 disease, we present significant bacteria and pathways characteristic of this disease.
- 13 February 2023
- Published by Springer Nature in International Microbiology
- Vol. 26 (3) , 601-610
Open AccessVariation of butyrate production in the gut microbiome in type 2 diabetes patients
Background: Diabetes mellitus type 2 is a common disease that poses a challenge to the healthcare system. The disease is very often diagnosed late. A better understanding of the relationship between the gut microbiome and type 2 diabetes can support early detection and form an approach for therapies. Microbiome analysis offers a potential opportunity to find markers for this disease. Next-generation sequencing methods can be used to identify the bacteria present in the stool sample and to generate a microbiome profile through an analysis pipeline. Statistical analysis, e.g., using Student’s t-test, allows the identification of significant differences. The investigations are not only focused on single bacteria, but on the determination of a comprehensive profile. Also, the consideration of the functional microbiome is included in the analyses. The dataset is not from a clinical survey, but very extensive. Results: By examining 946 microbiome profiles of diabetes mellitus type 2 sufferers (272) and healthy control persons (674), a large number of significant genera (25) are revealed. It is possible to identify a large profile for type 2 diabetes disease. Furthermore, it is shown that the diversity of bacteria per taxonomic level in the group of persons with diabetes mellitus type 2 is significantly reduced compared to a healthy control group. In addition, six pathways are determined to be significant for type 2 diabetes describing the fermentation to butyrate. These parameters tend to have high potential for disease detection. Conclusions: With this investigation of the gut microbiome of persons with diabetes type 2 disease, we present significant bacteria and pathways characteristic of this disease.